The Fed meets for two days, starting Tuesday, and is widely expected to taper back its monthly bond buying program by another $10 billion to $25 billion - and do little else.» Read More
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
A host of news out of France on Tuesday, with Alstom down more than 2 percent on reports that officials are investigating it for bribery.
Q: On Fast Money’s Trader Radar we look at the stock that was lighting up screens across Wall Street. A Brooklyn born pharmaceutical firm, this company makes Celebrex, Zoloft, and Viagra. But now investors are asking if it’s found a pot of gold in its new $300 million dollar plant in county Cork, Ireland. Who is it?
While thumbing through “Parade” magazine yesterday, the fluffy publication that you find tucked inside some Sunday newspapers, I noticed an ad for Pfizer’s stop-smoking drug Chantix. It caught my eye because the company had stopped doing what’s called “branded” advertising for the pill earlier this year because of new safety concerns...
It's the kind of artwork I'm sure they weren't happy to see at Pfizer spacer headquarters this morning. The torn company logo on the front page of the Newark Star-Ledger business section above the headline, "Signs of Wear and Tear."
On St. Patrick's Day (March 17), Bernie McGinn saw a lot of green for Ford: he told CNBC the automaker was a "buy." Since then, the troubled carmaker's shares are up 65.2 percent. Where's the head of McGinn Investment Management going now?
Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.
Earnings Season shifted into high gear, both corporate results and economic statistics were all over the proverbial map, and investors and traders found opportunities in some unlikely places.
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
Pfizer held its shareholder meeting Thursday morning at the historic Memphis hotel where the ducks march through the lobby. I haven't seen the spectacle yet, but I'm told it's quite the scene. Watch my exclusive interview with Chairman and CEO Jeff Kindler.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
Pfizer's slide continues. The stock has now fallen below $20 for the first time since 1997.
Stocks dropped mid-morning as oil is spiking just shy of $120. At this point, oil is a major drag on the markets. Speaking of stocks: we are about one-third through with first-quarter earnings, and it is not shaping up to be a great start.
Merck's revenues were light, but market reaction was positive. Eli Lilly's earnings were up sharply, but still disappointed the Street. So how does an investor play the results?
Monday has not been a great day for bank earnings. Last Monday it was Wachovia that disappointed, today futures dropped at 7 am ET as Bank of America came short of expectations.
Whenever the stock market rushes full speed ahead, it is hard not to look for the big let-down. That could be the case in the week ahead... Major earnings reports, housing data, annual shareholder meetings, and Tuesday's Pennsylvania presidential primaries are what traders will be watching to see if the trend continues.
Was Pfizer's miss, a prescription for disaster in Big Pharma? Should you sell drug makers ahead of earnings next week?
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
Google hits it out of the park, Merrill posts a loss but shares climb anyway and Pfizer plummets. All the earnings trades and much more right here.